Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091624
Status:
COMPLETED
Last Update Posted:
2016-12-01
First Post:
2004-09-13
Brief Title:
A Study of Doxil Vincristine and Decadron DVd CC-5013 in Relapsed Refractory Multiple Myeloma MM
Sponsor:
Celgene Corporation
Organization:
Celgene Corporation
Study Overview
Official Title:
A Phase I Study of DVd CC-5013 in Relapsed Refractory Multiple Myeloma MM
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Phase I Study of CC-5013 in combination with Doxil Vincristine and Decadron DVd in Subjects with Relapsed or Refractory Multiple Myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None